Loss widens slightly. Iovance Biotherapeutics reported a loss of $0.18 per share for Q4 2025, versus the expected loss of $0.18, in line with estimates. The biotechnology company’s net loss totaled $391 million for the quarter, reflecting continued investment in commercialization and research activities. Despite the wider-than-expected loss, shares surged 12.0% on volume of 44.6 million shares, suggesting investors focused on the revenue trajectory rather than near-term profitability.
Revenue accelerates sharply. Q4 revenue reached $86.8 million, up 28.7% from Q3’s $67.5 million and marking the fourth consecutive quarter of sequential growth since commercial launch. Gross profit of $90.3 million against cost of revenue of $173.2 million reflects the company’s early-stage commercialization dynamics. Operating loss of $398.2 million and EBITDA of negative $350.9 million underscore the heavy investment phase, with research and development expenses of $71.2 million and selling, general, and administrative costs of $36.4 million in the quarter.
Cash runway in focus. The company ended Q4 with $163.1 million in cash and cash equivalents against total debt of $49.4 million. Operating cash flow was negative $52.6 million, and free cash flow burned $61.9 million after $9.3 million in capital expenditures. With working capital of $304.3 million, the runway calculation will be critical as the company scales its cell therapy manufacturing and commercial operations.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.